Astragaloside IV ameliorates diabetic nephropathy in
Animals
Caspase 1
/ genetics
Cell Survival
/ drug effects
Cells, Cultured
Diabetes Mellitus, Type 2
/ complications
Diabetic Nephropathies
/ etiology
Gene Expression Regulation
/ drug effects
Inflammasomes
/ genetics
Inflammation
/ genetics
Interleukin-1beta
/ genetics
Kidney Cortex
/ drug effects
Male
Mice, Inbred C57BL
Microscopy, Electron, Transmission
NLR Family, Pyrin Domain-Containing 3 Protein
/ genetics
Obesity
/ complications
Podocytes
/ cytology
Saponins
/ pharmacology
Triterpenes
/ pharmacology
NLR family pyrin domain containing 3 inflammasome
astragaloside IV
diabetic nephropathy
inflammation
podocyte
proteinuria
Journal
International journal of molecular medicine
ISSN: 1791-244X
Titre abrégé: Int J Mol Med
Pays: Greece
ID NLM: 9810955
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
14
12
2020
accepted:
31
05
2021
entrez:
19
7
2021
pubmed:
20
7
2021
medline:
28
12
2021
Statut:
ppublish
Résumé
Diabetic nephropathy (DN) is a primary cause of end‑stage renal disease. Despite the beneficial effects of astragaloside IV (AS)‑IV on renal disease, the underlying mechanism of its protective effects against DN has not been fully determined. The aims of the present study were to assess the effects of AS‑IV against DN in
Identifiants
pubmed: 34278447
doi: 10.3892/ijmm.2021.4996
pii: 164
pmc: PMC8262660
doi:
pii:
Substances chimiques
Inflammasomes
0
Interleukin-1beta
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
Saponins
0
Triterpenes
0
astragaloside A
3A592W8XKE
Caspase 1
EC 3.4.22.36
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Nephrology (Carlton). 2020 Sep;25(9):659-666
pubmed: 32034833
Kidney Int. 2018 May;93(5):1198-1206
pubmed: 29398132
Am J Physiol Renal Physiol. 2003 Jun;284(6):F1138-44
pubmed: 12736165
Sci Rep. 2016 Sep 02;6:32545
pubmed: 27585918
Int J Mol Sci. 2020 Mar 13;21(6):
pubmed: 32183005
Diabetologia. 2007 Feb;50(2):471-80
pubmed: 17160673
Am J Nephrol. 2003 Sep-Oct;23(5):353-60
pubmed: 12915777
Curr Diab Rep. 2016 May;16(5):45
pubmed: 27053072
Mediators Inflamm. 2019 Feb 19;2019:1082497
pubmed: 30906223
Eur J Pharmacol. 2020 Nov 5;886:173449
pubmed: 32758570
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Life Sci. 2015 Aug 15;135:77-86
pubmed: 26006040
Mol Med Rep. 2019 Nov;20(5):4612-4622
pubmed: 31702040
Biomed Pharmacother. 2019 Jan;109:84-92
pubmed: 30396095
Lipids Health Dis. 2019 Apr 6;18(1):90
pubmed: 30954084
Biochem Pharmacol. 2020 May;175:113863
pubmed: 32081791
Kidney Int. 1992 Apr;41(4):1085-9
pubmed: 1513090
Kidney Int. 2012 Nov;82(9):1010-7
pubmed: 22718189
Ann Clin Lab Sci. 2015 Spring;45(3):256-63
pubmed: 26116588
Rev Diabet Stud. 2015 Spring-Summer;12(1-2):110-8
pubmed: 26676664
Biochem Biophys Res Commun. 2020 Jan 15;521(3):791-798
pubmed: 31703838
Fundam Clin Pharmacol. 2017 Feb;31(1):17-36
pubmed: 27567103
Nat Rev Nephrol. 2016 Jan;12(1):13-26
pubmed: 26568190
Mol Cell Endocrinol. 2018 Dec 15;478:115-125
pubmed: 30098377
Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2032-2045
pubmed: 28522654
Kidney Int. 2015 Jan;87(1):74-84
pubmed: 25075770
Biomed Pharmacother. 2017 Jul;91:208-219
pubmed: 28458159
Nat Rev Nephrol. 2011 Jun;7(6):327-40
pubmed: 21537349
Nephrology (Carlton). 2020 Oct;25 Suppl 2:12-45
pubmed: 33111477
Annu Rev Pathol. 2011;6:395-423
pubmed: 21261520
Transl Psychiatry. 2020 Jul 22;10(1):246
pubmed: 32699226
Exp Ther Med. 2020 Feb;19(2):1175-1182
pubmed: 32010286
BMC Nephrol. 2020 May 7;21(1):167
pubmed: 32380961
Am J Physiol Renal Physiol. 2019 May 1;316(5):F889-F897
pubmed: 30810354
Nat Med. 2013 Oct;19(10):1288-96
pubmed: 24056770
Nat Rev Cancer. 2019 Apr;19(4):197-214
pubmed: 30842595
J Am Soc Nephrol. 2016 Aug;27(8):2270-5
pubmed: 26832955